Company Culture

Quote


















To date, the Company has incurred recurring losses and negative cash flow from operations and has accumulated a deficit of $406,758,000 from inception through March 31, 2018 . As of March 31, 2018 , the Company had approximately $20,253,000 in cash and cash equivalents.
 






In management’s opinion, the uncertainty regarding future revenues raises substantial doubt about the Company’s ability to continue as a going concern without access to additional debt or equity financing, over the course of the next twelve months.
 






7.13 Financial Covenants. Permit revenues (under GAAP) from the sale in the ordinary course of business to third party customers of fluocinolone acetonide intravitreal implants (marketed on the Effective Date as “Illuvien”) by Borrower, on a trailing six (6) month basis, tested at the end of each quarter as set forth below, to be less than the Minimum Revenue Amount set forth below:

Quarter Ending:
Minimum Revenue Amount:
June 30, 2018
$[******]
September 30, 2018
$[******]
December 31, 2018
$[******]
March 31, 2019
$[******]
June 30, 2019
$[******]
September 30, 2019
$[******]
December 31, 2019
$[******]

https://www.sec.gov/Archives/edgar/data/1267602/000126760218000002/exhibit101.htm
 












While the Company has historically been able to raise additional capital through issuance of equity and/or debt financing, and while the Company has implemented a plan to control its expenses to satisfy its obligations due within one year from the date of issuance of these financial statements, the Company cannot guarantee that it will be able to maintain debt compliance, raise additional equity or increase revenue. Accordingly, there is substantial doubt about the Company’s ability to continue as a going concern within one year after these financial statements are issued.
 






We began paying a 2% royalty on net revenues and other related consideration to EyePoint effective July 1, 2017. This royalty amount will increase to 6% upon the earlier of December 12, 2018 or the receipt of the first marketing approval for ILUVIEN for the treatment of NIPU.
 






So let’s see they grew the global business vs. last year by 500k that’s 50 units. In Europe they announce the unit increase was because of distributors buying product and in US no growth because distributors didn’t buy. The way I see it distributors buy when they need to buy due to demand. Take away the distributors and global sales this quarter shows no growth. I ask you if there were no distributors would Alimera ship product if no one asked for it? No, they wouldn’t. Stop highlighting distributor behavior as the reason there is growth or no growth. It’s getting old.
 






Net loss for the three months ended June 30, 2018 was approximately $4.0 million, compared to a net loss of approximately $2.8 million for the three months ended June 30, 2017.
 












the Company has incurred recurring losses and negative cash flow from operations and has accumulated a deficit of $406,758,000

Executive Compensation

C. Daniel Myers, Director and Chief Executive Officer

2013 - $1,721,449

2014 - $638,727

2015 - $2,587,793

2016 - $1,494,217

2017 - $1,037,712

Richard S. Eiswirth, Chief Accounting Officer, President and Chief Financial Officer

2013 - $1,271,617

2014 - $425,587

2015 - $1,664,168

2016 - $1,031,078

2017 - $811,360

http://insiders.morningstar.com/tra...sation.action?t=ALIM&region=usa&culture=en-US
 






anonymous said:
So let’s see they grew the global business vs. last year by 500k that’s 50 units. In Europe they announce the unit increase was because of distributors buying product and in US no growth because distributors didn’t buy. The way I see it distributors buy when they need to buy due to demand. Take away the distributors and global sales this quarter shows no growth. I ask you if there were no distributors would Alimera ship product if no one asked for it? No, they wouldn’t. Stop highlighting distributor behavior as the reason there is growth or no growth. It’s getting old.
Click to expand...
 







I hope you see that you’re onto something. They have been lining up international distributors so that they can even make this paltry #. Add that in with “other” things that won’t be mentioned here and that is how they even got that small #. Remove both items and they’re into negative numbers. What happened to the 30m cash on hand? Ha ha.
 






Ricky has other jobs too and sits on another biotech board. Google it.

anonymous said:
the Company has incurred recurring losses and negative cash flow from operations and has accumulated a deficit of $406,758,000

Executive Compensation

C. Daniel Myers, Director and Chief Executive Officer

2013 - $1,721,449

2014 - $638,727

2015 - $2,587,793

2016 - $1,494,217

2017 - $1,037,712

Richard S. Eiswirth, Chief Accounting Officer, President and Chief Financial Officer

2013 - $1,271,617

2014 - $425,587

2015 - $1,664,168

2016 - $1,031,078

2017 - $811,360

http://insiders.morningstar.com/tra...sation.action?t=ALIM&region=usa&culture=en-US
Click to expand...
 












EyePoint evolves into a commercial-stage company in 2019, with the anticipated launches of both DEXYCUTM and YUTIQTM, subject to FDA approval.

Potential Indication: posterior segment uveitis

EyePoint filed an NDA in January 2018 and received a target PDUFA date of November 5, 2018 from the FDA.

YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg three-year micro-insert

In the U.S., posterior segment uveitis affects between 80,000 - 100,000 people.
 






O M G ;
it is so wired , in Germany no, no raised sales, in portugal no raised in sales,... only in spain raised stock by wholsales pharmacy, in italy raised stock in wholesale pharmacy , no raised sales in UK,
no raised sales in USA , so wtf is the record growth
I hope some day the SEC would have a deeper look in these bc mafia clan.
 






OMG , same old sh.. story ,
no raised sales in germany (only raised in stock of wholesale pharmacy ) , no raised sale in portugal , no raised sale in spain only raised in stock of wholesale pharmacy , same in italy raised in distributors
the geting old and alimera had to give a dame good profit (110-20%) for that.
wher should that .... record growth be
I hope some day the SEC have a deeper look in that BC .. mafia clan
 






Top Bottom
Back
Quote